Literature DB >> 30756242

Radiology reporting of low-grade glioma growth underestimates tumor expansion.

Chloe Gui1,2, Jonathan C Lau3,4,5, Suzanne E Kosteniuk3,4, Donald H Lee4,6, Joseph F Megyesi3,4.   

Abstract

BACKGROUND: An important aspect in the management of patients with diffuse low-grade gliomas (LGGs) involves monitoring the lesions via serial magnetic resonance imaging (MRI). However, radiological interpretations of LGG interval scans are often qualitative and thus difficult to use clinically.
METHODS: To contextualize these assessments, we retrospectively compared radiological interpretations of LGG growth or stability to volume change measured by manual segmentation. Tumor diameter was also measured in one, two, and three dimensions to evaluate reported methods for assessment of glioma progression, including RECIST criteria, Macdonald/RANO criteria, and mean tumor diameter/ellipsoid method.
RESULTS: Tumors evaluated as stable by radiologists grew a median volume of 5.1 mL (11.1%) relative to the comparison scan, and those evaluated as having grown had a median volume increase of 13.3 mL (23.7%). Diameter-based measurements corresponded well but tended to overestimate gold standard segmented volumes. In addition, agreement with segmented volume measurements improved from 17.6 ± 8.0 to 4.5 ± 5.8 to 3.9 ± 3.6 mm for diameter and from 104.0 ± 96.6 to 25.3 ± 36.8 to 15.9 ± 21.3 mL for volume with radiological measurements in one, two, and three dimensions, respectively. Measurement overestimation increased with tumor size.
CONCLUSIONS: Given accumulating evidence that LGG volume and growth are prognostic factors, there is a need for objective lesion measurement. Current radiological reporting workflows fail to appreciate and communicate the true expansion of LGGs. While volumetric analysis remains the gold standard for assessment of growth, careful diametric measurements in three dimensions may be an acceptable alternative.

Entities:  

Keywords:  Longitudinal growth quantification; Low-grade glioma; MRI; Neuro-oncology

Mesh:

Year:  2019        PMID: 30756242     DOI: 10.1007/s00701-018-03783-3

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  4 in total

1.  The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.

Authors:  Alba Corell; Sandra Ferreyra Vega; Nickoleta Hoefling; Louise Carstam; Anja Smits; Thomas Olsson Bontell; Isabella M Björkman-Burtscher; Helena Carén; Asgeir Store Jakola
Journal:  BMC Cancer       Date:  2020-05-20       Impact factor: 4.430

2.  A Quantitative Assessment of Pre-Operative MRI Reports in Glioma Patients: Report Metrics and IDH Prediction Ability.

Authors:  Hang Cao; E Zeynep Erson-Omay; Murat Günel; Jennifer Moliterno; Robert K Fulbright
Journal:  Front Oncol       Date:  2021-01-29       Impact factor: 6.244

Review 3.  EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.

Authors:  Michael Weller; Martin van den Bent; Matthias Preusser; Emilie Le Rhun; Jörg C Tonn; Giuseppe Minniti; Martin Bendszus; Carmen Balana; Olivier Chinot; Linda Dirven; Pim French; Monika E Hegi; Asgeir S Jakola; Michael Platten; Patrick Roth; Roberta Rudà; Susan Short; Marion Smits; Martin J B Taphoorn; Andreas von Deimling; Manfred Westphal; Riccardo Soffietti; Guido Reifenberger; Wolfgang Wick
Journal:  Nat Rev Clin Oncol       Date:  2020-12-08       Impact factor: 66.675

4.  Prediagnosis epilepsy and survival in patients with glioma: a nationwide population-based cohort study from 2009 to 2018.

Authors:  Mirketa Marku; Birthe Krogh Rasmussen; Federica Belmonte; Steinbjørn Hansen; Elisabeth Anne Wreford Andersen; Christoffer Johansen; Pernille Envold Bidstrup
Journal:  J Neurol       Date:  2021-06-24       Impact factor: 6.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.